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Abstract  
Objectives 
To investigate associations with joint damage in early Rheumatoid arthritis (RA), and how comorbid 
osteoarthritis (OA) might influence patient assessment and outcomes.  
Methods 
Baseline radiographs of hands/feet from 512 participants in the Early RA Network cohort, and 166 
after 3 (±1) years were scored for RA (erosions, joint space narrowing (JSN)) and OA (JSN, 
osteophytes (OST)) using validated atlases. DAS28-P was the proportion of DAS28 attributed to 
patient-reported factors. Adjusted odds ratios were calculated using logistic regression. 
Results 
OA was common at baseline in early RA (40% hand and 48% foot) and associated with RA 
radiographic score. Higher baseline RA scores were associated with increasing age and ESR, and 
lower DAS28-P.  OST scores were associated with higher age. 
DAS28 and patient reported outcomes improved, whereas RA and OA radiographic scores 
deteriorated by follow up.  Erosive progression was predicted by higher baseline erosions, female 
gender, better mental health and lower DAS28-P. Hand OST progression was predicted by baseline 
OST scores. Inflammatory disease activity was associated with erosive, but not with OA progression. 
Baseline hand OA predicted worse physical function at follow up, but radiographic progression did 
not explain changes in patient reported outcomes. 
Discussion 
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OA is a common comorbidity that might confound radiographic and clinical assessment but does not 
fully explain erosive progression or patient-reported outcomes in early RA.  Early RA management 
should address psychosocial factors and comorbidities, as well as joint inflammation. 
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Significance and Innovation 
1. Radiographic OA is common in the hands and feet of those with early RA, and hand 
OA might confound RA assessment and influence clinical outcome. 
2. RA and OA structural damage each might progress during the first 3 years after 
presentation with RA, despite significant improvements in DAS28 and patient 
reported outcomes.  
3. Measures of the proportion of DAS28 contributed by tender joint counts and VAS-
GH (DAS28-P), or mental health scores, might help stratify those at risk of rapid 
erosive progression. 
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Introduction  
Osteoarthritis (OA) is prevalent in the ageing population, including those in whom RA first becomes 
apparent (1). OA might confound RA assessment, being a comorbid source of joint pain, and either 
diagnosis might moderate pathogenesis of the other disease. Inflammatory RA might suppress 
osteophytosis (2), whereas suppression of RA inflammation with biologics reduced structural OA (3). 
The 28 joint Disease Activity Score (DAS28) is commonly used to measure inflammatory disease 
activity, and inform treatment/response decisions (4, 5). Although interpreted as a measure of 
inflammation, DAS28 is increased also in people with RA who have concurrent fibromyalgia (6).  We 
have recently derived the DAS28-P index, which is the proportion of DAS28 attributed to patient-
reported factors (7). DAS28-P was associated with higher TJC, VAS-GH, sensitivity to pain and worse 
pain progression in RA, as well as poorer mental health and fatigue scores (8). 
This study aimed to elucidate associations between joint damage, inflammation, pain and disability 
in people with early RA, and explore how comorbid OA might influence patient assessment and 
outcomes. 
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Methods 
Patients and Recruitment 
The ERAN inception cohort (9, 10) recruited from outpatient centres in the UK and Eire (10, 11) 
2002-2014. Patients were recruited following their first diagnosis of RA by a rheumatologist, and 
were not required to satisfy 1987 ACR RA criteria (46% at baseline and 45% at follow up fulfilled the 
criteria). Participants were monitored, treated and underwent radiography according to clinical need 
guided by schedule agreed by consensus prior to cohort recruitment. At baseline 41% were treated 
with methotrexate monotherapy, 25% sulphasalazine monotherapy and 24% a combination of non-
biologic DMARDs . Glucorticoid use was reported in 19% of participants at baseline. ERAN was 
approved by Trent Research Ethics Committee (ref 01/4/047) and all participants gave signed, 
informed consent in line with the Declaration of Helsinki.  
Data collection 
Standardised demographic and disease activity data were collected at baseline, 3-6 months, 1 year 
and yearly from baseline thereafter. Seropositive was defined as positive or strongly positivity for 
rheumatoid factor or antibodies to citrullinated proteins using local laboratory ranges. Participants 
also completed Short Form 36 (SF36)(12) and Health Assessment (HAQ; disability index) (13) 
questionnaires.  DAS28-P index was calculated as  the proportion of DAS28 attributed to patient-
reported factors (TJC and VAS-GH) in people with active RA (DAS28 > 3.2) (7). 
Radiography 
Plain radiographs of hands (anterior posterior) and feet (dorsoplantar) were collected from 6 centres 
with high recruitment to ERAN (Wye Valley NHS Trust, Sherwood Forest Hospitals NHS Foundation 
Trust, West Hertfordshire Hospitals NHS Trust, University Hospitals of Morecambe Bay NHS 
Foundation Trust, Yeovil District Hospital NHS Foundation Trust and North Bristol NHS Trust). 
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Radiographic images were from electronic data stores, or radiographic films were scanned using an 
Epson Expression® 10000XL (Seiko Epson, Japan). Participants were representative of those recruited 
at the selected ERAN centres for whom baseline radiographs were not collected (data not shown); 
baseline radiographic scores did not differ significantly between the patients attending different 
study centres (data not shown). Compared with those who only provided baseline images, people 
providing follow up images were older at baseline (mean 60 y vs 55 y, p < 0.001); had higher DAS28 
(mean 4.8 vs 4.4, p<0.036) and were less likely to be current smokers (29% vs 41%; p=0.012). 
Baseline radiographic scores did not differ significantly between those that provided follow up 
images, and those that provided baseline only images (data not shown). 
RA radiographic scoring 
Images of hands and feet were scored for erosions and JSN using the van der Heijde modification of 
Sharp’s method (14, 15) for erosions and JSN (16). Hand proximal interphalangeal (PIP) joints, MCP 
joints, carpo-metacarpal joints (CMC) 3-5, thumb base, radiocarpal joint, capitate-navicular-lunate 
joints, multangular navicular, trapezium/trapezoid metatarsophalangeal (MTP) and the hallux IP 
joints were assessed. Erosions were defined as regions with breakage or severe disruption of the 
intra-capsular marginal cortical bone. Summated erosion and JSN scores give a total ranging from 0 
to 448 with a maximum erosion score of 280 and JSN score of 168 (17). A 5 point progression in total 
score within 1 year is considered clinically important (18).  
Scoring was performed by one scorer (DMcW) who prior to the study was compared with an 
experienced scorer (KJ) (19) using 25 sets of hand and foot radiographs from the Early Rheumatoid 
Arthritis Study (ERAS) cohort (20). Intra-class correlation coefficients (ICC) for inter-observer 
variation were 0.80 (0.60 - 0.90) for erosions and 0.75 (0.57 - 0.86) for total/summated score (p < 
0.001 for all). Intra-observer ICCs were 0.92 (0.82 – 0.97) and 0.95 (0.87 – 0.98) respectively.  
OA radiographic scoring 
P9 
 
Validated radiographic scoring methods were used for hands (21, 22) and feet (23). At both sites, 
osteophytes (OST) and JSN were scored on a scale of 0-3 with reference to a photographic atlas.   For 
hand OA, scoring was performed for DIP joints, proximal interphalangeal (PIP) joints and the 1st 
carpo-metacarpal joint. Foot OA scoring was performed on MTP1, cuneo-metatarsal (CMT) joints 1 
and 2, cuneo-navicular joint and talonavicular joint (JSN only). Additionally, hand OA was classified 
when a joint from the hand OA atlas showed Kellgren and Lawrence grade ≥2 (24), and grades were 
also recorded for thumb (interphalangeal and  metacarpal) and MCP joints (digits 2-5). Foot OA was 
classified when any joint from the foot OA atlas showed an OST score  ≥2 (23). 
The single observer (DMcW) was compared to an experienced scorer (SD) using 20 pairs of hands 
from the GOAL study (25). Summated joint scores for the whole hand, DIP and PIP joints had inter-
observer ICCs (95% CI) of 0.78 (0.53–0.91); 0.89 (0.74–0.95) and 0.78 (0.52–0.91) respectively 
(p<0.001). Intra-observer ICCs (95% CI) were 0.94 (0.72 – 0.96), 0.98 (0.93 – 0.99); and 0.98 (0.96 – 
0.99), respectively. Foot OA scoring by the single scorer (DMcW) was compared to an experienced 
scorer (MM) using 60 pairs of feet from the CAS-F study (26). For summated OST scores, inter-
observer ICC (95% CI) was 0.81 (0.69 – 0.89),  and intra-observer ICC (95% CI) was 0.84 (0.58 – 0.94)).  
 
ERAN study participants were assessed in a blinded, random order, with images from different 
centres randomly mixed. However, radiographs were viewed chronologically within each person (14). 
Baseline radiographs were within one calendar year of the baseline visit. A total of 512 people had at 
least one baseline radiograph which yielded 459 pairs of fully scoreable hands and feet at baseline. 
Follow up radiographs were selected from 3 (±1) year follow up time point giving a final sample size 
of 166 people with hand and foot radiographs scored at baseline and follow up.  
  
Statistical analysis 
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Radiographic scores, and their progression were primary outcome variables, and complete case 
analysis was performed. Each outcome variable was divided by the median for calculation of odds 
ratios (OR), adjusted OR (aOR), and 95% confidence intervals (CI). Spearman’s rank correlation 
coefficients were calculated for analysis during follow up. Baseline DAS28 scores were classified into 
EULAR disease activity groups (Low: 0-3.19 (for whom DAS28-P is not calculated (7)), moderate: 
3.20-5.19, and high: ≥ 5.20)(27); BMI was classified into WHO groups (<25; 25.0-29.9; ≥30)(28). 
Other continuous variables were divided into tertiles of increasing severity. Univariate analyses were 
not adjusted for multiple comparisons. Logistic regression models were all adjusted for age, gender 
and either DAS28 (or all 4 DAS28 components) and length of follow up (2–3 years, or 3–4 years). 
Additionally, they were adjusted for those variables with p values<0.10 in univariate analysis . For 
cross-sectional logistic regression analyses of baseline only data, adjusting variables were selected 
(RA radiographic scores - DAS28-P; or ESR, SJC, TJC and VAS-GH, plus symptom duration (erosions 
only) or mental health (JSN only). Hand OA - DAS28-P, serology and symptom duration (all), plus 
mental health (OST only) or physical function (JSN only). Foot OA - DAS28-P (all), plus HAQ (OST only), 
or serology, mental health, bodily pain, vitality and physical function (JSN only). Analysis of baseline 
hand OA and disability at 3 years were adjusted for baseline disability measure (HAQ or SF36-
Physical Function), age, gender and DAS28. Statistical analysis was performed using SPSS version 21 
(IBM Corp, USA). Statistical significance was taken when p < 0.05. 
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Results 
Demographics and clinical characteristics 
Baseline characteristics of the study group are shown in Table 1.  
Cross sectional associations of baseline radiographic scores 
Radiographic scores are shown in Table 2. The median (IQR) RA score was 6 (4-12); the hand OST 
score was 9 (0-5); and the foot OST score was 2 (1-4). Patients with erosive changes on hand or foot 
radiographs displayed higher OA radiographic scores, both for OST and for JSN, both in hands and in 
feet (Table 2). Furthermore, OA was observed within DIP joints in 30% of cases, in PIP joints in 12% 
and in the thumb base in 13% of cases. In the foot, OA in MTP1 was observed in 44% of cases and 
CMT1 joint in 4% of cases. Evidence of OA was also observed in joints beyond the scope of the OA 
atlases, with OA in MCP joints in 19%; thumb IP joint in 15%;  MTP2-5 in 6%; and hallux IP joints in 
4% of cases. RA and OA radiographic changes were occasionally observed within the same joint (See 
Supplementary figure 1). 
Univariate analyses were used to explore cross-sectional associations at baseline (Table 3). Age was 
consistently associated with higher radiographic scores and DAS28-P was associated with lower 
radiographic scores in most measures (Table 3). Symptom duration, serology, and ESR were also 
associated with some of the radiographic scores.  
Further analysis at baseline was performed, using logistic regression to assess which factors were 
independently associated with baseline radiographic scores.  Baseline erosions score was associated 
(aOR, (95% CI)) with age (2.57 (1.77 to 3.72)); longer duration (1.49 (1.06 to 2.29)); and lower DAS28-
P (0.68 (0.48 to 0.97)). Analysis after the inclusion of ESR, SJC, TJC and VAS-GH, and removal of 
DAS28 and DAS28-P, showed that erosions were associated with higher ESR (1.77 (1.26 to 2.47), and 
lower TJC scores (0.63 ( 0.43 to 0.93). Similar analysis of OA at baseline showed that age was 
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independently associated with higher OST score (aOR 3.93 (95% CI 2.39 to 6.47), p<0.001). Higher 
OA JSN score in the hands was associated with greater age (aOR 3.37 (2.08 – 5.47), p<0.001) and 
female gender (aOR 2.36 (1.16 – 4.78), p=0.018). At baseline, age was associated with higher foot 
OST scores (aOR 3.02 (95% CI 2.11 to 4.34), p<0.001). Foot JSN scores were associated with age (aOR 
1.93 (1.19 – 3.14), p=0.008) and female gender (aOR 2.16 (1.05 – 4.46), p=0.036).  
Radiographic progression in early RA 
At 3 (±1) year follow up there were n=166 cases that provided radiographic images with scores 
(median (IQR)) of total; 14 (7 – 23), erosions; 5 (2 – 10) and JSN; 7 (4 – 13). These represented 
increases of total; 6 (3 – 12), p<0.001; erosions; 3 (1 – 6) p<0.001, and JSN; 3 (1 – 7) p<0.001. 89% 
(148/166) of participants had one or more erosions in either hands (80%) or feet (65%), and people 
with erosions scored at follow up were significantly older than those without (mean age 57 vs 45 
years, P<0.05). Radiographic OA scores (median (IQR)) at follow up were hand OST; 1 (0 - 7) and JSN; 
1 (0 – 3), and foot OST; 2 (1 – 4) and JSN; 4 (3 – 5). Hand OST progressed by 0 (0 – 2), p<0.001 and 
foot OST by 0 (0 – 1), p<0.001. Hand OA JSN progressed 0 (0 - 1), p=0.046 and foot JSN by 1 (-1 – 2), 
p<0.001 (Table 2). At follow up, 41% (68/166) of participants were classified as having hand OA, and 
47% (78/166) had foot OA. Hand OA and foot OA were newly classified at follow up in respectively 
15% (17/111) and 25% (24/96) of participants who were not classified as having OA at baseline. 
Further examination of OA progression showed that those people without OST’s at baseline in 
scored hand or foot joints progressed to KL score classification as hand OA or foot OA in 4% (4/92) 
and 3% (3/33) of cases respectively. Radiographs that were scored JSN=0 and OST=0 at baseline, 
were rare in those with OA at follow up.  1.4% (1/74)  of those with hand OA at follow up had no JSN 
and no OST at baseline. 
Predictors of radiographic progression in early RA 
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Table 4 presents the univariate analyses of baseline characteristics associated with greater changes 
in radiographic scores. Age and radiographic scores were the only baseline variables significantly 
associated with changes in total or JSN RA radiographic scores. Increases in erosion scores were 
associated with higher age, higher baseline erosion score, more hand OA, lower DAS28-P and better 
vitality and mental health (table 4).  Changes in hand OST scores were predicted at the univariate 
level by higher age, higher baseline TJC, hand OST score and foot OST score (Table 4). Greater 
changes in foot OST scores were associated with baseline hand OST scores (table 4). Univariate 
analysis of OA JSN scores are shown in supplementary Table 1. 
Multivariable logistic regression was used to examine the data for independent predictors of higher 
than median radiographic change. Above median increases in erosion scores were predicted by 
higher baseline erosions score, female gender, better mental health and lower DAS28-P (table 5).  
Greater than median OST score progression for the hands was predicted by baseline hand OST score 
only (Table 5).  
Clinical associations of radiographic change in early RA 
To investigate the contribution of inflammatory disease activity to radiographic progression, 
cumulative values for DAS28 or its components were calculated from baseline to year 2. Higher 
cumulative ESR was associated with greater RA radiographic progression, but not with OA 
progression (supplementary Table 2). Higher cumulative DAS28 or VAS-GH was each associated with 
increased JSN change for both RA hand and OA foot scores (supplementary Table 2). Progression of 
OST radiographic scores was not significantly associated with cumulative DAS28 or any of its 
components (supplementary Table 2). 
At 3 year follow up, we investigated whether the presence of OA at baseline was associated with 
worse clinical outcome. Hand OA at baseline was associated with worse SF36-physical function at 
follow up (hand OA: 30(14) vs no hand OA 37 (15), p=0.001), and worse HAQ disability scores at 
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follow up (hand OA:1.1 (0.8) vs no hand OA 0.8 (0.7), p=0.015). Adjustments for confounders 
removed the significance of these associations (Physical Function β=-3.0 (95% CI -9.2 to 3.2, p=0.336 
and HAQ β=0.2 (95% CI -0.1 to 0.4, p = 0.197)). Corresponding univariate or multivariable 
associations were not significant between baseline hand OA and bodily pain or DAS28, neither 
between foot OA classification and any clinical outcome. Furthermore, we investigated whether 
changes in radiographic scores may mediate clinical outcome in early RA. Progression of RA and OA 
radiographic scores were not significantly associated with worsening in SF36 Physical Function score, 
HAQ disability, or SF36 Bodily Pain score, even after adjusting for change in DAS28 (all standardised 
beta values <0.23, p ≥ 0.091). 
Discussion 
We found that radiographic OA was common in early RA, and RA and OA structural progression both 
occured during the first 3 years after diagnosis. Associations between RA and OA structural changes 
indicate that comorbid OA might confound disease assessment in people with early RA. 
Inflammation might mediate erosive progression, but non-inflammatory factors measured using 
mental health scores and DAS28-P moderate the ability of DAS28 to predict erosive progression in 
early RA. Factors such as DAS28-P or mental health deserve investigation as novel stratification tools 
for treatments targeting radiographic progression in early RA. 
Sustained inflammatory disease activity causes erosive progression in RA (29, 30). A majority (61%) 
of participants with follow-up radiographs displayed RA radiographic progression of a magnitude 
considered “clinically important” (18). This might reflect inadequate disease suppression by 
monotherapies commonly used at the time of patient recruitment (31), and selection bias for those 
with more active inflammatory disease. Previous attempts to predict erosive progression in RA have 
focussed on those factors anticipated to augment RA pathogenesis (38). Baseline radiographic scores 
predicted radiographic progression, supporting the early classification of patient subgroups as either 
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erosive/non-erosive (32), or either osteoarthritic/non-osteoarthritic. Inflammation, seropositive 
status and erosions have been associated early RA (33). However, high baseline inflammatory 
disease activity might be associated with a greater potential to respond to treatment (34) or a 
greater likelihood of allocation to more intensive treatment in routine clinical practice (31). 
Seropositivity and DAS28 were not independent predictors of subsequent radiographic progression 
in our study, and the relationship between damage and serology might be stronger in uncontrolled 
disease (35). 
 
Higher DAS28-P and worse mental health might identify a group of patients with augmented central 
pain processing, such as those with RA and concurrent fibromyalgia (6, 7, 36) who display less 
structural damage than those with RA alone (37). Our findings highlight the importance of non-
inflammatory mechanisms as moderators of disease assessment, and prediction of erosive 
progression might be improved by inclusion of DAS28-P and measures of mental health.  
Our study confirms relationships between RA and OA radiographic features at baseline and their 
progression (1, 39). RA or OA radiographic scoring achieves specificity by inclusion of disease-
characteristic joint groups (e.g. metacarpophalangeal (MCP) joints for RA and distal interphalangeal 
(DIP) joints for OA). Comparable with non-RA populations, the predominant joints affected by OA in 
our study were DIP (40) and 1st MTP joints (26)). However, either disease might affect joints that are 
scored for the other disease. Associations between RA and OA might reflect the propensity of both 
diseases to cause cartilage damage and JSN (14), or effects of age and other confounding factors. 
Prolonged synovitis and erosive damage might eventually lead to co-occurring OA (22), although this 
association was not apparent in this early RA cohort. Similarly, OA at baseline did not significantly 
moderate the risk of erosive damage over the same period. In summary, OA can be considered a 
comorbid condition in early RA. We show that comorbid OA might influence inflammatory disease 
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assessment in RA, for example by contributing to swollen joint counts in the hands, or to disability 
(foot OA). 
Consistent with previous studies, radiographic OA was associated with increasing age (41) and 
increasing age was also associated with worse baseline RA radiographic scores (42).. Older patients 
might present with more advanced disease, perhaps because they might accept joint symptoms as a 
sign of normal ageing. Peak RA incidence has shifted to older age groups in recent decades, and the 
burden of concurrent RA and OA is likely to further increase. Lack of association between OA and 
BMI or gender might reflect study power or moderating effects of RA. 
Interpretation of our data is subject to several methodological limitations. Radiographic scoring by a 
single observer eliminated inter-observer variability, but similar results might not be obtained by 
other investigators. RA and OA features were scored separately, with more than several weeks 
between scoring of the same films for respective diseases. However, scorers cannot be blinded to 
concurrent radiographic features. All cortical disruptions were scored as erosions (43), and uneven 
cortical bone surfaces adjacent to osteophytes might have influenced RA radiographic scoring. 
Scoring images in chronological sequence permits back-checking of difficult images, but knowing 
that all participants had early RA might have led us to overestimate radiographic progression. 
ERAN documents a `real life’ inception cohort of people who present to secondary care services with 
early RA and the frequency of radiographic assessment varied, although inclusion of follow up period 
as a covariate did not affect our conclusions. Study centre inclusion was not random, and follow up 
radiographs were available for only a subgroup which differed from the total ERAN population in 
baseline disease activity and smoking, both of which are risk factors for poor outcomes. Reported RA 
radiographic scores in the current study are comparable to previous reports (44), but higher than 
others (45, 46). Our included participants might have had worse clinical features and undergone 
more frequent radiographic follow up, and our findings may be representative of those with more 
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active RA. OA pathology might precede radiographic change (47), and few people progressed to 
newly classified OA. Our findings apply mainly to the progression of OA that was present at first 
presentation with RA, and further research should investigate whether the presence of early RA 
affects OA incidence. 
In conclusion, OA is a common comorbidity in early RA, and both RA and OA structural progression 
occur during the first 3 years after diagnosis. Associations between RA and OA structural changes 
indicate the potential for comorbid OA to confound early RA disease assessment. Inflammation 
mediates erosive progression, but non-inflammatory factors moderate the ability of DAS28 to 
predict erosive progression in early RA. Holistic approaches to RA management are indicated, that 
address psychosocial factors and comorbidities, as well as joint inflammation. 
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Table 1: Baseline demographic and clinical characteristics of study population  
 
All cases with baseline radiographs  
 
Demographics    
n= 512 
Female 65% 
Age (years) 58 (48 - 69) 
BMI (kg.m
-2
) 26.8 (24.1 - 30.5) 
Smoking history 62% 
RA disease characteristics 
Duration (months) 6 (3 - 12) 
Seropositive 62% 
DAS28 4.6 (3.4 - 5.7) 
VAS-GH (0-100mm) 40 (20 - 62) 
TJC (0-28) 5 (1 - 11) 
SJC (0-28) 4 (1 - 8) 
ESR (mm/hr) 20 (11 -37) 
CRP (ng/dL) 7 (3 - 20) 
DAS28-P 0.45 (0.38 - 0.50) 
Patient reported 
outcome measures 
 HAQ (0-3) 1.0 (0.4 - 1.5) 
SF36-Bodily pain  35 (11) 
SF36-Physical Function 31 (15) 
SF36-Vitality 43 (11) 
SF36-Mental Health 47 (11) 
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Median (IQR) or percentage prevalence, with SF36 data presented as mean (sd). SF36 scores represent normed values, where normal UK population values are mean 50 (SD 
10). Seropositive was defined as positive for rheumatoid factor and/or citrullinated proteins. Groups compared using Mann-Whitney U-tests and χ² tests. Significance 
denoted as * p < 0.05, ** p<0.01. BMI- body mass index, HAQ-health assessment questionnaire, DAS28-P – proportion of patient-reported components in the DAS28 index. 
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Table 2: Baseline radiographic scores in early RA (univariate comparisons) 
 
 
Study group   Erosions in hand or foot ≥1   Hand K≥L2 OA   Foot osteophyte scored >=2 
  Total    No   Yes 
 
No   Yes   No   Yes 
Radiographic Scores 
    
  
       Erosions 72% 
 
0% 100% 
 
65% 
 
83% ** 
 
64% 
 
81% ** 
RA score 6 (4 - 12) 
 
2 (1 – 4) 
 
8 (5 - 15) 
 
4 (2 - 8) 
 
11 (6 - 21) ** 
 
5 (2 - 8) 
 
8 (4 - 16) ** 
Erosion score 2 (0 - 5) 
 
0 (0 – 0) 
 
3 (2 - 6) 
 
1 (0 - 3) 
 
3 (1 - 8) ** 
 
1 (0 - 3) 
 
3 (1 - 6) ** 
JSN score (RA) 4 (2 - 8) 
 
2 (1- 4) 
 
5 (2 - 10) ** 
 
3 (1 - 5) 
 
6 (4 - 12) ** 
 
3 (1 - 6) 
 
5 (3 - 11) ** 
Hand OA 40% 
 
24% 
 
46% ** 
 
0% 100% 
 
30% 
 
52% ** 
Hand OST score 1 (0 - 5) 
 
0 (0 - 2) 
 
2 (0 - 6) ** 
 
0 (0 - 1) 
 
6 (3 - 10) ** 
 
0 (0 - 3) 
 
2 (0 - 6) ** 
Hand JSN score 1 (0 - 3) 
 
0 (0 - 1) 
 
1 (0 - 3) ** 
 
0 (0 - 1) 
 
3 (1 - 6) ** 
 
0 (0 - 2) 
 
1 (0 - 3) ** 
Foot OA 48% 
 
33% 
 
54% ** 
 
39% 
 
61% ** 
 
0% 100% 
Foot OST score 2 (1 - 4) 
 
2 (0 - 3) 
 
2 (1 - 4) ** 
 
2 (0 - 3) 
 
3 (2 - 5) ** 
 
1 (0 - 2) 
 
4 (3 - 5) ** 
Foot JSN score 4 (2 - 5) 
 
3 (2 - 4) 
 
5 (2 - 10) ** 
 
3 (2 - 5) 
 
4 (3 - 6) ** 
 
3 (2 - 5) 
 
4 (3 - 6) ** 
Baseline radiographic scores and radiographic classifications (median (IQR)) or percentage. ** p<0.01; * p<0.05 in Yes vs No comparisons (univariate, 
unadjusted analyses). 
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Table 3: Univariate associations between baseline radiographic scores and baseline patient and disease characteristics 
    Rheumatoid arthritis scoring   Osteoarthritis scoring 
      
Above median 
radiographic score  
Above median 
erosions score  
   
Above median JSN 
score   
Above median hand 
OST score  
Above median hand JSN 
score  
Above median foot OST 
score  
Above median foot JSN 
score 
      OR (95% CI)    OR (95% CI)     OR (95% CI)    OR (95% CI)    OR (95% CI)    OR (95% CI)    OR (95% CI)  
Demographics                         
Gender  Female  1.01 (0.69 - 1.49)  
 
1.13 (0.77 - 1.66)  
 
0.89 (0.61 - 1.32)  
 
1.20 (0.83 - 1.75) 
 
1.02 (0.70 - 1.48) 
 
0.69 (0.47 - 1.01) 
 
1.07 (0.73 - 1.58) 
Age (years) 
Low 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
2.40 (1.51 - 3.85)** 
 
2.63 (1.65 - 
4.21)**  
2.41 (1.51 - 
3.85)**  
5.16 (3.03 - 8.79) 
 
2.83 (1.77 - 4.54) 
 
5.10 (3.02 - 8.64)** 
 
1.91 (1.22 - 3.01)** 
High 
tertile  
9.13 (5.37 - 
15.51)**  
6.61 (3.92 - 
11.18)**  
9.85 (5.70 - 
17.03)**  
18.06 (10.25 - 31.83) 
 
15.33 (8.83 - 26.63) 
 
6.78 (3.97 - 11.59)** 
 
3.80 (2.33 - 6.18)** 
BMI (kg.m
-2
) 
<25  1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
25-
29.99  
0.96 (0.60 - 1.55)  
 
1.12 (0.70 - 1.81)  
 
1.26 (0.78 - 2.04)  
 
1.02 (0.64 - 1.61) 
 
0.83 (0.53 - 1.32) 
 
1.23 (0.76 - 1.99) 
 
0.69 (0.43 - 1.11) 
30+  0.93 (0.55 - 1.57)  
 
1.07 (0.64 - 1.82)  
 
1.05 (0.62 - 1.78)  
 
0.98 (0.59 - 1.62) 
 
1.11 (0.67 - 1.84) 
 
1.21 (0.72 - 2.06) 
 
0.53 (0.31 - 0.89)* 
Smoking history Yes  0.99 (0.68 - 1.46)  
 
1.19 (0.81 - 1.75)  
 
0.97 (0.66 - 1.42)  
 
0.93 (0.64 - 1.35) 
 
0.79 (0.54 - 1.14) 
 
1.30 (0.88 - 1.91) 
 
0.87 (0.60 - 1.28) 
Disease characteristics and RA measures 
           
Symptom 
duration (months) 
Low 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.76 (0.48 - 1.21)  
 
0.70 (0.44 - 1.11)  
 
0.77 (0.49 - 1.23)  
 
0.64 (0.41 - 1.01) 
 
0.57 (0.36 - 0.89)* 
 
0.84 (0.53 - 1.33) 
 
0.94 (0.60 - 1.50) 
High 
tertile  
1.39 (0.88 - 2.18)  
 
1.53 (0.96 - 2.43)  
 
0.96 (0.61 - 1.52)  
 
0.56 (0.36 - 0.87)* 
 
0.64 (0.41 - 1.00) 
 
1.06 (0.68 - 1.67) 
 
1.05 (0.67 - 1.65) 
Serology Positive 0.96 (0.63 - 1.47)  
 
0.88 (0.57 - 1.35)  
 
0.70 (0.45 - 1.07)  
 
0.58 (0.39 - 0.88)* 
 
0.62 (0.41 - 0.94)* 
 
0.77 (0.51 - 1.18) 
 
0.64 (0.42 - 0.99) 
DAS28-ESR  
<3.2  1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
3.2 - 
5.19  
0.76 (0.43 - 1.34)  
 
0.86 (0.49 - 1.52)  
 
0.77 (0.44 - 1.37)  
 
0.91 (0.53 - 1.56) 
 
0.99 (0.58 - 1.69) 
 
0.93 (0.53 - 1.64) 
 
0.81 (0.46 - 1.42) 
5.2+  0.93 (0.52 - 1.65)  
 
1.18 (0.67 - 2.10)  
 
0.80 (0.45 - 1.42)  
 
1.20 (0.70 - 2.07) 
 
1.52 (0.88 - 2.61) 
 
1.28 (0.73 - 2.24) 
 
0.68 (0.39 - 1.21) 
VAS-GH (0-100mm) 
Low 
tertile  
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.82 (0.52  - 1.29) 
 
0.69 (0.43  1.10) 
 
0.70 (0.44 - 1.11) 
 
0.79 (0.51 - 123) 
 
0.69 (0.44 - 1.07) 
 
0.85 (0.54 - 1.35) 
 
0.78 (0.49 - 1.24) 
High 
tertile  
0.81 (0.51 - 1.29) 
 
0.84 (0.53 - 1.34) 
 
0.58 (0.36 - 0.93)* 
 
0.76 (0.48 - 1.18) 
 
0.74 (0.47 - 1.16) 
 
0.89 (0.56 - 1.40) 
 
0.44 (0.28 - 0.71)** 
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TJC (0-28) 
Low 
tertile  
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.69 (0.44 - 1.08) 
 
0.63 (0.40 - 1.00) 
 
0.62 (0.39  0.98) 
 
0.90 (0.58 - 1.40) 
 
1.11 (0.72 - 1.72) 
 
0.77 (0.49 - 1.21) 
 
0.81 (0.51 - 1.27) 
High 
tertile  
0.69 (0.43 - 1.09) 
 
0.72 (0.45 - 1.14) 
 
0.79 (0.50 - 1.24) 
 
1.04 (0.68 - 1.61) 
 
1.17 (0.76 - 1.80) 
 
1.11 (0.71 - 1.75) 
 
0.63 (0.40 - 1.00) 
SJC (0-28) 
Low 
tertile  
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
1.13 (0.71 - 1.78) 
 
1.20 (0.76 - 1.89) 
 
1.01 (0.64 - 1.59) 
 
1.41 (0.91 - 2.19) 
 
1.31 (0.85 - 2.03) 
 
0.90 (0.57 - 1.42) 
 
0.85 (0.53 - 1.34) 
High 
tertile  
1.41 (0.87 - 2.26) 
 
1.53 (0.95 - 2.47) 
 
1.09 (0.68 - 1.76) 
 
1.77 (1.11 - 2.81)* 
 
1.58 (1.00 - 2.50) 
 
1.41 (0.87 - 2.27) 
 
0.73 (0.45 - 1.17) 
ESR (mm/hr) 
Low 
tertile  
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
1.91 (1.13 - 3.24)* 
 
2.87 (1.69 - 
4.89)**  
1.67 (1.00  2.81) 
 
1.49 (0.90 - 2.46) 
 
1.51 (0.92 - 2.48) 
 
1.19 (0.70 - 2.00) 
 
1.17 (0.69 - 1.96) 
High 
tertile  
2.44 (1.42 - 4.19)* 
 
3.37 (1.95 - 
5.83)**  
1.82 (1.07 - 3.10)* 
 
2.05 (1.23 - 3.44)** 
 
2.64 (1.57 - 4.45)** 
 
1.51 (0.89 - 2.54) 
 
1.02 (0.61 - 1.70) 
DAS28-P  
Low 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.45 (0.25 - 0.82)* 
 
0.46 (0.25 - 0.85)* 
 
0.49 (0.27 - 0.89)* 
 
0.62 (0.35 - 1.10) 
 
0.57 (0.32 - 1.03) 
 
1.00 (0.56 - 1.79) 
 
0.84 (0.47 - 1.52) 
High 
tertile  
0.44 (0.24 - 0.80)* 
 
0.38 (0.21 - 
0.69)**  
0.38 (0.21 - 
0.70)**  
0.29 (0.16 - 0.52)** 
 
0.35 (0.19 - 0.63)** 
 
0.61 (0.33 - 1.10) 
 
0.48 (0.26 - 0.86)* 
Patient reported outcome measures 
           
HAQ (0-3) 
Low 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.78 (0.49 - 1.24)  
 
0.93 (0.59 - 1.48)  
 
0.74 (0.46 - 1.19)  
 
0.79 (0.50 - 1.23) 
 
0.85 (0.54 - 1.32) 
 
1.31 (0.82 - 2.10) 
 
0.69 (0.43 - 1.10) 
High 
tertile  
0.94 (0.59 - 1.50)  
 
0.94 (0.59 - 1.49)  
 
0.93 (0.58 - 1.49)  
 
1.08 (0.69 - 1.70) 
 
1.29 (0.82 - 2.03) 
 
1.72 (1.07 - 2.76)* 
 
0.67 (0.42 - 1.08) 
SF36-Bodily Pain  
Good 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
1.09 (0.65 - 1.83)  
 
0.74 (0.44 - 1.25)  
 
1.12 (0.66 - 1.90)  
 
0.78 (0.48 - 1.29) 
 
0.92 (0.56 - 1.51) 
 
0.81 (0.48 - 1.37) 
 
0.65 (0.38 - 1.11) 
Poor 
tertile  
1.00 (0.60 - 1.66)  
 
0.78 (0.47 - 1.30)  
 
0.67 (0.40 - 1.12)  
 
0.92 (0.56 - 1.52) 
 
0.77 (0.47 - 1.27) 
 
1.09 (0.65 - 1.83) 
 
0.43 (0.25 - 0.73)** 
SF36-Physical 
function  
Good 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
1.18 (0.70 - 1.97)  
 
1.05 (0.63 - 1.75)  
 
1.43 (0.85 - 2.38)  
 
1.29 (0.79 - 2.10) 
 
1.59 (0.97 - 2.59) 
 
1.03 (0.62 - 1.71) 
 
0.62 (0.37 - 1.05) 
Poor 
tertile  
1.53 (0.92 - 2.56)  
 
1.23 (0.74 - 2.06)  
 
1.52 (0.91 - 2.54)  
 
1.45 (0.89 - 2.37) 
 
1.52 (0.93 - 2.48) 
 
1.18 (0.71 - 1.96) 
 
0.69 (0.41 - 1.15) 
SF36-Vitality  
Good 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
1.02 (0.62 - 1.70)  
 
1.08 (0.64 - 1.80)  
 
0.87(0.52 - 1.46)  
 
0.87 (0.53 - 1.41) 
 
1.08 (0.66 - 1.75) 
 
1.42 (0.86 - 2.37) 
 
0.65 (0.39 - 1.08) 
Poor 
tertile  
1.17 (0.70 - 1.95)  
 
0.98 (0.58 - 1.63)  
 
0.76 (0.46 - 1.28)  
 
1.05 (0.64 - 1.72) 
 
1.19 (0.73 - 1.94) 
 
1.10 (0.66 - 1.85) 
 
0.54 (0.32 - 0.91)* 
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SF36-Mental 
health  
Good 
tertile  
1  
 
1  
 
1  
 
1 
 
1 
 
1 
 
1 
Middle 
tertile  
0.87 (0.52 - 1.43)  
 
0.83 (0.50 - 1.38)  
 
0.66 (0.40 - 1.10)  
 
0.63 (0.39 - 1.02) 
 
0.67 (0.41 - 1.09) 
 
0.72 (0.44 - 1.19) 
 
0.62 (0.38 - 1.04) 
Poor 
tertile  
0.95 (0.57 - 1.57)     0.74 (0.44 - 1.22)     0.61 (0.36 - 1.01)    0.79 (0.49 - 1.28)   0.66 (0.41 - 1.07)   0.86 (0.52 - 1.43)   0.46 (0.28 - 0.77)** 
 
Baseline radiographic variables and their univariate, unadjusted associations with demographic and clinical measures. Baseline radiographic scores were 
dichotomised into above and below median for generation of odds ratios (OR) and 95% confidence intervals (CI). The risks for above median scores are 
shown. Variables with a statistically significant result are highlighted in bold. ** p<0.01, * p<0.05. 
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Table 4: Radiographic progression in early RA (univariate analyses) 
Erosions and osteophytes 
Above/below 
median change in 
erosion score (2-
4yr)  
   
Above/below 
median change in 
hand OST score 
  
 Above/below 
median change in 
Foot OST 
OR (95% CI)     OR (95% CI)    OR (95% CI)  
Demographics 
   
 
 
Gender Female 1.10 (0.58 – 2.08)  
 
0.99 (0.52 - 1.87) 
 
1.39 (0.73 - 2.67) 
Age (years) 
Low tertile 1  
 
1 
 
1 
Middle tertile 
2.55 (1.18 – 
5.51) *  
1.85 (0.84 - 4.09) 
 
0.79 (0.37 - 1.70) 
High tertile 
3.68 (1.66 – 
8.15) **  
3.72 (1.70 - 8.15)** 
 
1.57 (0.73 - 3.35) 
BMI (kg.m-2) 
<25 1  
 
1 
 
1 
25-29.99 1.19 (0.55 - 2.57)  
 
1.05 (0.49 - 2.24) 
 
1.24 (0.57 - 2.70) 
30+ 1.05 (0.45 - 2.45)  
 
1.35 (0.59 - 3.10) 
 
1.20 (0.51 - 2.86) 
Smoking 
history 
Yes 0.89 (0.47 - 1.68) 
 
0.72 (0.38 - 1.34) 
 
0.57 (0.30 - 1.07) 
Disease Characteristics and RA 
measures   
   Symptom 
duration 
(months) 
Low tertile 1  
 
1 
 
1 
Middle tertile 1.05 (0.47 - 2.34)  
 
1.29 (0.60 - 2.77) 
 
0.95 (0.44 - 2.04) 
High tertile 1.88 (0.88 - 4.01)  
 
1.34 (0.62 - 2.87) 
 
0.85 (0.39 - 1.88) 
Serology Seropositive 1.85 (0.87 - 3.92)  
 
0.74 (0.35 - 1.55) 
 
1.11 (0.52 - 2.38) 
DAS28-ESR 
<3.2 1  
 
1 
 
1 
3.2 - 5.19 2.13 (0.79 - 5.69)  
 
1.00 (0.38 - 2.64) 
 
1.22 (0.46 - 3.22) 
5.2+ 2.57 (0.95 - 6.98)  
 
1.84 (0.70 - 4.82) 
 
1.59 (0.61 - 4.15) 
VAS-GH (0-
100mm) 
Low tertile 1 
 
1 
 
1 
Middle tertile 0.66 (0.30 - 1.42) 
 
0.48 (0.22 - 1.03) 
 
0.69 (0.32 - 1.48) 
High tertile 0.83 (0.39 - 1.75) 
 
0.64 (0.31 - 1.33) 
 
0.63 (0.29 - 1.35) 
TJC (0-28) 
Low tertile 1 
 
1 
 
1 
Middle tertile 1.75 (0.83 - 3.71) 
 
1.94 (0.88 - 4.25) 
 
1.21 (0.56 - 2.61) 
High tertile 0.96 (0.44 - 2.08) 
 
2.91 (1.32 - 6.41)* 
 
1.16 (0.54 - 2.52) 
SJC (0-28) 
Low tertile 1 
 
1 
 
1 
Middle tertile 1.65 (0.77 - 3.50) 
 
1.24 (0.58 - 2.66) 
 
0.96 (0.45 - 2.09) 
High tertile 1.56 (0.74 - 3.26) 
 
1.36 (0.66 - 2.77) 
 
1.34 (0.64 - 2.79) 
ESR (mm/hr) 
Low tertile 1 
 
1 
 
1 
Middle tertile 1.50 (0.65 - 3.48) 
 
0.85 (0.37 - 1.94) 
 
1.43 (0.62 - 3.26) 
High tertile 2.13 (0.94 - 4.82) 
 
1.29 (0.58 - 2.85) 
 
1.26 (0.55 - 2.88) 
CRP (ng/dL) 
Low tertile 1 
 
1 
 
1 
Middle tertile 0.81 (0.31 - 2.17) 
 
1.42 (0.50 - 4.08) 
 
0.72 (0.27 - 1.97) 
High tertile 1.00 (0.39 - 2.59) 
 
1.25 (0.48 - 3.25) 
 
1.77 (0.67 - 4.67) 
DAS28-P 
Low tertile 1  
 
1 
 
1 
Middle tertile 0.46 (0.18 – 1.17)  
 
0.41 (0.17 - 1.00) 
 
1.00 (0.41 - 2.47) 
High tertile 
0.33 (0.13 – 
0.85) *  
0.81 (0.34 - 1.98) 
 
0.77 (031 - 1.92) 
Outcome Measures 
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HAQ (0-3) 
Low tertile 1  
 
1 
 
1 
Middle tertile 1.17 (0.53 - 5.59)  
 
1.41 (0.65 - 3.06) 
 
0.99 (0.46 - 2.14) 
High tertile 0.93 (0.44 - 1.96)  
 
1.06 (0.48 - 2.36) 
 
0.59 (0.26 - 1.33) 
SF36-Bodily 
Pain 
Good tertile 1  
 
1 
 
1 
Middle tertile 1.06 (0.44 - 2.58)  
 
0.81 (0.37 - 1.77) 
 
0.54 (0.24 - 1.22) 
Poor tertile 0.47 (0.20 - 1.07)  
 
1.03 (0.42 - 2.50) 
 
0.68 (0.27 - 1.69) 
SF36-Physical 
function 
Good tertile 1  
 
1 
 
1 
Middle tertile 1.23 (0.52 - 2.91)  
 
1.30 (0.58 - 2.90) 
 
1.41 (0.61 - 3.24) 
Poor tertile 0.66 (0.29 - 1.49)  
 
1.00 (0.44 - 2.27) 
 
1.06 (0.45 - 2.50) 
SF36-Vitality 
Good tertile 1  
 
1 
 
1 
Middle tertile 0.50 (0.21 - 1.16)  
 
1.28 (0.57 - 2.89) 
 
0.51 (0.22 - 1.19) 
Poor tertile 
0.39 (0.16 - 
0.94) *  
0.84 (0.36 - 1.95) 
 
1.05 (0.44 - 2.48) 
SF36-Mental 
health 
Good tertile 1  
 
1 
 
1 
Middle tertile 0.68 (0.29 - 1.55)  
 
0.64 (0.29 - 1.43) 
 
0.46 (0.20 - 1.05) 
Poor tertile 
0.28 (0.12 - 
0.68) ** 
   0.65 (0.28 - 1.47) 
 
0.95 (0.41 - 2.21) 
Radiographic scores 
  
   
RA total score 
Low tertile 1 
 
1 
 
1 
Middle tertile 2.42 (1.12 - 5.20)* 
 
1.31 (0.61 - 2.81) 
 
1.19 (0.55 - 2.57) 
High tertile 
5.47 (2.44 - 
12.27)**  
2.22 (1.03 - 4.78) 
 
1.57 (0.73 - 3.40) 
Erosion score 
Low tertile 1 
 
1 
 
1 
Middle tertile 1.65 (0.77 - 3.58) 
 
1.31 (0.60 - 2.85) 
 
0.70 (0.32 - 1.52) 
High tertile 
4.59 (2.01 - 
10.50)**  
1.95 (0.89 - 4.31) 
 
1.18 (0.54 - 2.59) 
Hand OST 
Low tertile 1 
 
1 
 
1 
Middle tertile 2.72 (1.17 - 6.32) 
 
2.15 (0.93 - 4.96) 
 
0.31 (0.12 - 0.83)* 
High tertile 1.75 (0.86 - 3.58) 
 
7.19 (3.35 - 
15.43)** 
 
2.16 (1.04 - 4.50)* 
Foot OST 
Low tertile 1 
 
1 
 
1 
Middle tertile  0.94 (0.46 - 1.91) 
 
2.15 (0.93 - 4.96) 
 
0.65 (0.32 - 1.32) 
High tertile  1.46 (0.64 - 3.33)   
7.19 (3.35 - 
15.43)** 
  0.62 (0.28 - 1.37) 
 
Baseline variables and their univariate, unadjusted associations with progression of erosions and 
osteophyte scores in those that provided follow up images. Follow up radiographic change scores 
were dichotomised into above and below median for generation of odds ratios (OR) and 95% 
confidence intervals (CI). The risks for above median changes are shown. Structural change divided 
into above/below median and OR (95% CI) calculated. Variables with significant results highlighted in 
bold.  ** p<0.01, * p<0.05. 
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Table 5: Logistic regression for structural change in early RA 
 
 
Erosive progression (hands and feet)   Hand osteophyte progression   Foot osteophyte progression 
aOR (95% CI) p   aOR (95% CI) p   aOR (95% CI) p 
Age (years) 1.76 (0.64 - 4.80) 0.271   0.78 (0.35 - 1.72) 0.532   1.31 (0.53 - 3.22) 0.555 
Female 4.54 (1.28 - 16.08) 0.019 
 
0.77 (0.29 - 2.03) 0.599 
 
2.14 (0.75 - 6.09) 0.158 
DAS28 1.19 (0.34 - 4.19) 0.789 
 
1.78 (0.68 - 4.68) 0.241 
 
1.17 (0.40 - 3.43) 0.782 
SF36-Bodily Pain 0.86 (0.39 - 1.89) 0.713 
 
Not used 
  
Not used 
 SF36-Mental health 0.45 (0.20 - 1.00) 0.049 
 
Not used 
  
Not used 
 SF36-Vitality 1.25 (0.51 - 3.01) 0.629 
 
Not used 
  
Not used 
 DAS28-P 0.45 (0.22 - 0.90) 0.025 
 
0.77 (0.42 - 1.41) 0.396 
 
1.36 (0.71 - 2.59) 0.350 
RA radiographic score Not used 
  
0.85 (0.47 - 1.54) 0.598 
 
1.38 (0.71 - 2.67) 0.343 
Erosions 2.14 (1.02 - 4.50) 0.044 
 
Not used 
  
Not used 
 Hand OST 0.68 (0.30 - 1.55) 0.354 
 
2.46 (1.26 - 4.80) 0.008 
 
1.16 (0.59 - 2.31) 0.670 
Foot OST 0.89 (0.44 - 1.83) 0.757 
 
1.15 (0.62 - 2.14) 0.652 
 
0.64 (0.32 - 1.26) 0.197 
Duration of follow up (years) 1.15 (0.39 - 3.35) 0.802   1.09 (0.41 - 2.93) 0.865   1.83 (0.64 - 5.17) 0.257 
 
Logistic regression models, adjusted for baseline factors and the risk of higher than median progression of erosions and osteophytes (n=166). Significant 
results highlighted in bold.  
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Supplementary figure 1: Selected radiographic images from different people showing coexistence of 
erosions and osteophytes. A. Proximal interphalangeal joints with erosions and osteophytes. B. 1st 
metatarso-phalangeal joint with evidence of osteophytosis and erosion formation. C. Metacarpo-
phalangeal joints showing erosions and visible osteophytes (OA was not scored for this joint group). 
D. Metatarso-phalangeal joints with erosions visible and osteophyte in the first joint. Arrows denote 
osteophytes. Arrow heads denote erosions.
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Supplementary table1: Clinical and demographic associations of joint space narrowing progression in early RA 
Joint space narrowing 
Above/below median change in 
Sharp/van der Heijde JSN score 
for hands and feet (2-4yr)    
Above/below median change 
in Altman OA Hand JSN score   
Above/below median change 
in Menz OA Foot JSN score 
OR (95% CI)  p    OR (95% CI)  p    OR (95% CI)  p  
Demographics 
  
 
  
 
  
Gender Female 0.82 (0.43 - 1.55)  0.623  
 
1.48 (0.71 - 3.09) 0.367 
 
1.12 (0.59 - 2.13) 0.747 
Age Low tertile 1  
 
 
1 
  
1 
 Middle tertile 1.64 (0.76 - 3.52)  0.247  
 
1.46 (0.60 - 3.54) 0.504 
 
0.89 (0.42 - 1.87) 0.849 
High tertile 3.13 (1.43 – 6.86)  0.007  
 
2.43 (1.05 - 5.66) 0.041 
 
0.64 (0.30 - 1.37) 0.336 
BMI <25 1  
 
 
1 
  
1 
 25-29.99 0.60 (0.28 - 1.31)  0.239  
 
0.60 (0.26 - 1.38) 0.285 
 
1.36 (0.64 - 2.92) 0.444 
30+ 1.06 (0.45 - 2.48)  >0.999  
 
0.75 (0.30 - 1.87) 0.647 
 
1.41 (0.60 - 3.33) 0.515 
Smoking history Yes 
1.53 (0.80 - 2.91) 0.256 
 
1.24 (0.61 - 2.51) 0.599 
 
1.28 (0.68 - 2.40) 0.519 
Disease Characteristics and RA measures 
 
      Symptom 
duration 
Low tertile 1  
 
 
1 
  
1 
 Middle tertile 0.58 (0.26 - 1.31)  0.224  
 
0.50 (0.22 - 1.17) 0.137 
 
1.16 (0.54 - 2.49) 0.845 
High tertile 0.92 (0.44 - 1.95)  0.851  
 
0.65 (0.29 - 1.46) 0.308 
 
2.11 (0.95 - 4.67) 0.075 
Serology Seropositive 1.64 (0.77 - 3.50)  0.256  
 
1.71 (0.70 - 4.17) 0.280 
 
0.98 (0.46 - 2.08) >0.99 
DAS28-ESR <3.2 1  
 
 
1 
  
1 
 3.2 - 5.19 
0.90 (0.35 - 2.32)  >0.999  
 
3.58 (0.96 - 13.83) 0.062 
 
1.98 (0.77 - 5.13) 0.235 
5.2+ 
1.66 (0.64 - 4.33)  0.338  
 
2.97 (0.78 - 11.24) 0.160 
 
1.55 (0.60 - 3.96) 0.479 
VAS-GH Low tertile 1 
 
 
1 
  
1 
 Middle tertile 0.94 (0.43 - 2.05) >0.99 
 
1.03 (0.44 - 2.40) >0.99 
 
0.74 (034 - 1.58) 0.445 
High tertile 1.85 (0.87 - 3.94) 0.130 
 
1.36 (0.61 - 3.04) 0.542 
 
0.95 (0.44 - 2.01) >0.99 
TJC Low tertile 1 
 
 
1 
  
1 
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Middle tertile 1.17 (0.55 - 2.46) 0.708 
 
2.32 (0.97 - 5.52) 0.061 
 
0.73 (0.34 - 1.57) 0.446 
High tertile 1.04 (0.48 - 2.25) >0.99 
 
1.64 (0.67 - 4.02) 0.370 
 
0.82 (0.38 - 1.75) 0.698 
SJC Low tertile 1 
 
 
1 
  
1 
 Middle tertile 0.89 (0.42 - 1.90) 0.848 
 
0.86 (0.34 - 2.17) 0.818 
 
0.88 (0.41 - 1.87) 0.847 
High tertile 1.84 (0.87 - 3.87) 0.135 
 
2.39 (1.10 - 5.22) 0.033 
 
0.78 (0.38 - 1.61) 0.579 
ESR (mm/hr) Low tertile 1 
 
 
1 
  
1 
 Middle tertile 1.49 (0.64 - 3.46) 0.395 
 
2.02 (0.75 - 5.45) 0.217 
 
0.54 (0.24 - 1.24) 0.212 
High tertile 2.54 (1.12 - 5.78) 0.040 
 
3.04 (1.18 - 7.84) 0.024 
 
1.46 (0.65 - 3.30) 0.412 
CRP (ng/dL) Low tertile 1 
 
 
1 
  
1 
 Middle tertile 1.65 (0.61 - 4.47) 0.448 
 
2.26 (0.73 - 6.94) 0.169 
 
1.07 (0.41 - 2.82) >0.99 
High tertile 1.77 (0.67 - 4.67) 0.327 
 
1.00 (0.39 - 2.59) >0.99 
 
2.70 (1.00 - 7.26) 0.055 
DAS28-P Low tertile 1  
 
 
1 
  
1 
 Middle tertile 1.73 (0.69 – 4.38)  0.350 
 
0.93 (0.37 - 2.31) >0.99 
 
0.73 (0.30 - 1.80) 0.647 
High tertile 0.57 (0.23 – 1.45)  0.346  
 
0.58 (0.21 - 1.55) 0.326 
 
1.29 (0.53 - 3.19) 0.649 
Outcome Measures 
  
      HAQ Low tertile 1  
 
 
1 
  
1 
 Middle tertile 1.39 (0.62 - 3.11)  0.538  
 
1.41 (0.57 - 3.49) 0.503 
 
1.12 (0.52 - 2.41) 0.845 
High tertile 2.19 (1.03 - 4.68)  0.057  
 
2.06 (0.85 - 5.04) 0.128 
 
1.13 (0.51 - 2.51) 0.840 
SF36-Bodily Pain Good tertile 1  
 
 
1 
  
1 
 Middle tertile 1.57 (0.65 - 3.77)  0.377  
 
0.83 (0.34 - 2.06) 0.816 
 
1.23 (0.55 - 2.76) 0.682 
Poor tertile 0.89 (0.39 - 2.02)  0.836  
 
1.64 (0.63 - 4.32) 0.336 
 
0.85 (0.35 - 2.12) 0.819 
SF36-Physical 
function 
Good tertile 1  
 
 
1 
  
1 
 Middle tertile 0.90 (0.38 - 2.13)  0.830 
 
1.27 (0.53 - 3.04) 0.660 
 
1.13 (0.50 - 2.57) 0.835 
Poor tertile 1.29 (0.57 - 2.92)  0.679  
 
0.71 (0.27 - 1.82) 0.632 
 
1.15 (0.49 - 2.66) 0.831 
SF36-Vitality Good tertile 1  
 
 
1 
  
1 
 Middle tertile 1.32 (0.58 - 3.02)  0.535  
 
2.23 (0.82 - 6.04) 0.153 
 
2.26 (0.98 - 5.21) 0.063 
Poor tertile 1.06 (0.45 - 2.52)  >0.999  
 
2.21 (0.80 - 6.10) 0.145 
 
1.71 (0.72 - 4.08) 0.275 
SF36-Mental 
health 
Good tertile 1  
 
 
1 
  
1 
 Middle tertile 1.48 (0.65 - 3.35)  0.409  
 
2.82 (1.09 - 7.30) 0.041 
 
0.99 (0.44 - 2.24) >0.99 
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Poor tertile 0.77 (0.33 - 1.79)  0.669  
 
1.68 (0.61 - 4.59) 0.449 
 
0.88 (0.38 - 2.05) 0.831 
Radiographic scores 
  
      RA total score Low tertile 1 
 
 
1 
  
1 
 Middle tertile 2.42 (1.12 - 5.20) 0.035 
 
2.51 (1.07 - 5.93) 0.037 
 
1.20 (0.56 - 2.58) 0.700 
High tertile 3.56 (1.64 - 7.75) 0.001 
 
1.90 (0.77 - 4.59) 0.185 
 
0.84 (0.39 - 1.79) 0.700 
Erosion score Low tertile 1 
 
 
1 
  
1 
 Middle tertile 2.67 (1.20 - 5.91) 0.020 
 
1.76 (0.73 - 4.26) 0.277 
 
0.95 (0.44 - 2.03) >0.99 
High tertile 4.05 (1.77 - 9.23) 0.001 
 
1.90 (0.78 - 4.64) 0.188 
 
1.08 (0.49 - 2.37) >0.99 
JSN score Low tertile 1 
 
 
1 
  
1 
 Middle tertile 1.58 (0.77 - 3.27) 0.270 
 
1.25 (0.55 - 2.87) 0.674 
 
1.24 (0.60 - 2.60) 0.578 
High tertile 2.25 (1.03 - 4.90) 0.052 
 
1.93 (0.83 - 4.49) 0.138 
 
0.98 (0.44 - 2.15) >0.99 
Hand OST Low tertile 1 
 
 
1 
  
1 
 Middle tertile 0.78 (0.34 - 1.78) 0.677 
 
2.64 (1.08 - 6.45) 0.050 
 
0.61 (0.27 - 1.39) 0.298 
High tertile 2.72 (1.30 - 5.70) 0.011 
 
3.67 (1.70 - 7.92) 0.001 
 
0.97 (0.47 - 1.99) >0.99 
Hand JSN Low tertile 1 
 
 
1 
  
1 
 Middle tertile 1.06 (0.45 - 2.52) >0.99 
 
1.84 (0.71 - 4.75) 0.210 
 
0.97 (0.42 - 2.27) >0.99 
High tertile 2.39 (1.17 - 4.85) 0.022 
 
2.35 (1.14 - 4.88) 0.026 
 
1.15 (0.57 - 2.34) 0.722 
Foot OST Low tertile 1 
 
 
1 
  
1 
 Middle tertile 2.04 (0.99 - 4.21) 0.068 
 
2.64 (1.08 - 6.45) 0.050 
 
1.12 (0.55 - 2.28) 0.857 
High tertile 2.10 (0.92 - 4.82) 0.095 
 
3.67 (1.70 - 7.92) 0.001 
 
0.60 (0.28 - 1.32) 0.237 
Foot JSN Low tertile 1 
 
 
1 
  
1 
 Middle tertile 1.49 (0.71 - 3.11) 0.351 
 
1.84 (0.71 - 4.75) 0.210 
 
0.31 (0.14 - 0.69) 0.004 
High tertile 1.68 (0.75 - 3.79) 0.225   2.35 (1.14 - 4.88) 0.026   0.12 (0.05 - 0.28) <0.001 
Univariate analysis of baseline variables associated with progression of joint space narrowing scores. Structural change divided into above/below median 
and OR (95% CI) calculated. Significant results highlighted in bold. 
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Supplementary Table 2: Univariate associations between cumulative DAS28 components (from 0 to 2 years) and radiographic progression  
    Rheumatoid arthritis   Osteoarthritis 
    Total change 
 
Erosions change 
 
JSN change   
Hand OST 
change 
  Hand JSN change   
Foot OST 
change 
  Foot JSN change 
  Tertile OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI)   OR (95% CI) 
DAS28 1 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 2.92 (0.88 - 9.67) 
 
3.52 (1.05 - 11.83) * 
 
2.05 (0.63 - 6.69) 
 
1.63 (0.49 - 5.34) 
 
3.04 (0.78 - 11.81) 
 
1.67 (0.48 - 5.74) 
 
2.08 (0.59 - 7.38) 
 
3 2.19 (0.69 - 6.93) 
 
2.19 (0.69 - 6.93) 
 
3.54 (1.09 - 11.51) * 
 
1.12 (0.35 - 3.59) 
 
1.21 (0.29 - 5.01) 
 
1.53 (0.48 - 4.88) 
 
5.83 (1.71 - 19.90) ** 
ESR 1 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 1.00 (0.31 - 3.22) 
 
4.20 (1.23 - 14.37) * 
 
0.49 (0.15 - 1.60) 
 
1.60 (0.49 - 5.29) 
 
0.94 (0.23 - 3.85) 
 
1.30 (0.40 - 4.24) 
 
1.56 (0.48 - 5.06) 
 
3 5.00 (1.45 - 17.27) * 
 
7.29 (2.03 - 26.10) ** 
 
4.49 (1.26 - 16.01) * 
 
1.60 (0.49 - 5.29) 
 
2.62 (0.72 - 9.54) 
 
0.58 (0.17 - 2.05) 
 
1.56 (0.48 - 5.06) 
       
        SJC 1 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 1.15 (0.54 - 3.93) 
 
1.46 (0.54 - 3.90) 
 
1.30 (0.48 - 3.52) 
 
1.92 (0.68 - 5.46) 
 
0.88 (0.26 - 2.91) 
 
0.95 (0.33 - 2.72) 
 
1.42 (0.51 - 3.96) 
 
3 1.85 (0.70 - 4.92) 
 
1.13 (0.43 - 2.98) 
 
2.69 (1.00 - 7.28) 
 
1.50 (0.53 - 4.21) 
 
1.71 (0.56 - 5.21) 
 
1.86 (0.67 - 5.15) 
 
2.71 (0.96 - 7.64) 
       
        TJC 1 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 0.69 (0.26 - 1.82) 
 
0.55 (0.21 - 1.46) 
 
0.87 (0.33 - 2.30) 
 
2.35 (0.84 - 6.60) 
 
1.80 (0.62 - 5.25) 
 
1.42 (0.51 - 3.97) 
 
0.72 (0.26 - 1.98) 
 
3 0.89 (0.34 - 2.34) 
 
0.48 (0.18 - 1.29) 
 
1.85 (0.70 - 4.92) 
 
1.57 (0.57 - 4.34) 
 
0.49 (0.14 - 1.68) 
 
1.51 (0.54 - 4.24) 
 
2.00 (0.71 - 5.68) 
       
        VAS-GH 1 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 1.75 (0.66 - 4.69) 
 
1.06 (0.40 - 2.82) 
 
3.93 (1.39 - 11.12) * 
 
1.23 (0.45 - 3.37) 
 
1.16 (0.40 - 3.40) 
 
1.82 (0.66 - 5.04) 
 
1.08 (0.39 - 2.96) 
  3 1.55 (0.58 - 4.15)   0.51 (0.19 - 1.36)   3.07 (1.09 - 8.60) *   0.78 (0.28 - 2.17)   0.65 (0.21 - 2.05)   0.87 (0.31 - 2.46)   3.60 (1.22 - 10.64) * 
 
Univariate analysis of cumulative DAS28, and its components, from people with baseline, 1 and 2 year data available. Cumulative DAS28, ESR, SJC, TJC and VAS-GH were 
compared to radiographic progression rates. ** p<0.01, * p<0.05. 
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